Oakstone Living Legends in Psychopharmacology From Evidence Base to Advances in Treatment 2023

30 $

+ Include: 18 videos + 2 pdfs, size: 13.2 GB

+ Target Audience: psychiatry physican

Categories: ,


+ Include: 18 videos + 2 pdfs, size: 13.2 GB

+ Target Audience: psychiatry physican

+ Sample video: contact me for sample video

+ Information:

Expert-Led Psychopharmacology CME

Living Legends in Psychopharmacology: From Evidence Base to Advances in Treatment centers on the treatment of usual psychiatric patients with emphasis on the difficult to treat or treatment-resistant. Continuing medical education lectures will enhance your ability to choose treatments as you gain an understanding of the interface between psychiatric, neurological, and medical illness.

Legendary faculty review new antipsychotic medications and treatment augmentation, potential new uses for mood stabilizers, the neurobiologic mechanisms of depression and the role of inflammation, the importance of a therapeutic alliance when prescribing psychotropic medications, and more. With this online CME program, you’ll explore current evidence-based and emerging treatments for:

  • Schizophrenia and bipolar disorder
  • Bipolar and treatment-resistant depression
  • TMS and ECT
  • Anxiety spectrum and sleep disorders
  • PTSD
  • Alcohol and substance abuse disorders
  • Women’s mental health issues
  • Child, adolescent, and geriatric psychopharmacology

Date of Original Release: June 1, 2023
Estimated Time to Complete: 13.00 hours

CME credit is awarded upon successful completion of a course evaluation and post-test.

Learning Objectives

At the completion of this course, you should be able to:

  • Describe lessons learned from genomic sequencing of patients with psychiatric illnesses
  • Identify unsolved problems regarding the pharmacologic treatment of schizophrenia and learning more effective treatments
  • Describe emerging theories and treatments of bipolar disorder, difficult-to-treat depression, bipolar depression, and anxiety disorder
  • Outline the perils and possibilities of psychedelics and ketamine
  • Recognize when to utilize ECT and TMS for treatment-resistant depression
  • Illustrate emerging treatments for PTSD
  • Review sleep disorders commonly comorbid with psychiatric illness, and appropriate use of medications and treatment
  • Review interface of medicine and psychiatry with a focus on cancer, cardiovascular disease
  • Review the interface of neurology and psychiatry with an emphasis on functional neurological disease, hysteria, movement disorders, pain, OCD and others
  • Summarize the use of genetic tests, serum level measurements, and drug combinations in treatment-resistant depression
  • Identify the current role of pharmacotherapy in the treatment of substance use disorders including alcohol, opioids, and cannabis
  • Review the role of pharmacotherapy in the treatment of psychiatric disorders throughout women’s reproductive lifespan, with a focus on the premenstrual, prenatal, postpartum, and perimenopausal periods
  • Examine the latest advances and problems associated with treatment approaches in the child, adolescent, and geriatric populations

Intended Audience

Practicing clinicians in the field of psychopharmacology drawn from the following disciplines: psychiatry, medicine, nursing, nurse practitioners, and psychology.


+ Topics:

1. Lessons Learned from the DNA of Patients with Psychiatric Disorders – Daniel Weinberger, MD.mp4
2. Neurology and Psychiatry Interface – Martin Samuels, MD, DSc (hon).mp4
3. The Interface of Medical and Psychiatric Disorders – Focus on Cancer and Heart Disease – Charles Nemeroff, MD, PhD.mp4
4. Tackling Unsolved Problems in the Pharmacological Treatment of Schizophrenia – Cognitive Impairment, Negative Symptoms, and Partial Treatment Response – Philip Harvey, PhD.mp4
5. Panel Discussion – Philip Harvey, PhD, Charles Nemeroff, MD, PhD, Martin Samuels, MD, DSc (hon), and Daniel Weinberger, MD.mp4
6. Pharmacological Treatment of Bipolar Disorder – Ross Baldessarini, MD, DSc (hon).mp4
7. Anxiety – Treat the Symptom or Treat the Disorder When First Line Therapies Fail – Stephen Stahl, MD, PhD, DSc (hon).mp4
8. Neurobiology and Treatment of Post-traumatic Stress Disorder – Charles Nemeroff, MD, PhD.mp4
9. Panel Discussion – Ross Baldessarini, MD, DSc (hon), Charles Nemeroff, MD, PhD.mp410. Psychopharmacologic Treatment of Sleep Disorders – Sogol Javaheri, MD.mp4
11. Treatment Resistant Depression – Stephen Stahl, MD, PhD, DSc (hon).mp4
12. Psychedelics and Potential Drugs of Abuse as Antidepressants – Alan Schatzberg, MD.mp4
13. Pharmacotherapy of Substance Use Disorders – Roger Weiss, MD.mp4
14. Panel Discussion – Barbara Coffey, MD, MS, Sogol Javaheri, MD, Alan Schatzberg, MD, Stephen Stahl, MD, PhD, DSc (hon), and Roger Weiss, MD.mp4
15. Child and Adolescent Psychopharmacology – Current Treatment for Best Practices – Barbara Coffey, MD, MS.mp4
16. Psychopharmacology Across the Reproductive Lifespan – From Menarche to Menopause – Ariadna Forray, MD.mp4
17. Geriatric Psychopharmacology – Elizabeth Crocco, MD.mp4
18. Panel Discussion – Barbara Coffey, MD, MS, Elizabeth Crocco, MD, and Ariadna Forray, MD.mp4


There are no reviews yet.

Be the first to review “Oakstone Living Legends in Psychopharmacology From Evidence Base to Advances in Treatment 2023”

Your email address will not be published. Required fields are marked *